Symbols / XTLB $0.62 +3.87%
XTLB Chart
About
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.90M |
| Enterprise Value | 549.11M | Income | -6.31M | Sales | 968.00K |
| Book/sh | -0.00 | Cash/sh | 259000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 6.09 | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | 567.26 | Quick Ratio | 0.46 |
| Current Ratio | 0.70 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.90 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2016-06-01 08:00 | ROA | -240.56% |
| ROE | -5.77% | ROIC | — | Gross Margin | -232.85% |
| Oper. Margin | -8.54% | Profit Margin | 0.00% | Shs Outstand | 9.46M |
| Shs Float | 481.32M | Short Float | 0.91% | Short Ratio | 0.90 |
| Short Interest | — | 52W High | 2.57 | 52W Low | 0.53 |
| Beta | 0.73 | Avg Volume | 754.20K | Volume | 25.05K |
| Target Price | — | Recom | None | Prev Close | $0.60 |
| Price | $0.62 | Change | 3.87% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.62
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$0.62
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2015-05-08 | init | HC Wainwright & Co. | — → Buy | $6 |
- XTL Biopharmaceuticals (NASDAQ: XTLB) NeuroNOS deal LOI expires with Beyond Air - Stock Titan ue, 10 Mar 2026 20
- XTL Biopharmaceuticals Ltd. Receives Nasdaq Non-Compliance Notification Regarding Stockholders' Equity Requirements | XTLB Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- XTL Biopharmaceuticals faces Nasdaq delisting notice - Investing.com Fri, 27 Feb 2026 08
- XTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI Expires - TipRanks ue, 10 Mar 2026 20
- Nasdaq notice hits XTL Biopharma over sub-$2.5M equity level - Stock Titan Fri, 23 Jan 2026 08
- XAIR Stock More Than Doubled Today — What’s Driving The Rally? - Stocktwits ue, 13 Jan 2026 08
- XTL Biopharmaceuticals schedules extraordinary general meeting for February - Investing.com ue, 13 Jan 2026 08
- XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Advance Autism Therapeutics with Leading Scientific Team - Quiver Quantitative ue, 13 Jan 2026 08
- Nasdaq flags small drugmaker after shares trade under $1 - Stock Titan Wed, 24 Dec 2025 08
- XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination - TipRanks Fri, 27 Feb 2026 22
- XTL Biopharmaceuticals stock falls on Nasdaq delisting notice - Investing.com Fri, 27 Feb 2026 08
- XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing - Stock Titan Fri, 27 Feb 2026 08
- Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today? - TipRanks Wed, 08 Oct 2025 07
- XTL Biopharmaceuticals Faces Liquidation of Web Data Subsidiary After Insolvency Ruling - TipRanks Mon, 23 Feb 2026 08
- Subsidiary liquidation at XTL Biopharmaceuticals (NASDAQ: XTLB) risks $1.5M loan - Stock Titan Mon, 23 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 119.89K | 0.00 | 0.00 | 340.17K |
| TaxRateForCalcs | 0.11 | 0.00 | 0.00 | 0.23 |
| NormalizedEBITDA | -2.00M | -728.00K | -854.00K | -2.51M |
| TotalUnusualItems | 1.07M | -1.05M | -493.00K | 1.48M |
| TotalUnusualItemsExcludingGoodwill | 1.07M | -1.05M | -493.00K | 1.48M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -1.03M | -1.78M | -1.35M | 435.00K |
| ReconciledDepreciation | 199.00K | 0.00 | 1.00K | 1.00K |
| ReconciledCostOfRevenue | 280.00K | 0.00 | 0.00 | |
| EBITDA | -930.00K | -1.78M | -1.35M | -1.03M |
| EBIT | -1.13M | -1.78M | -1.35M | -1.03M |
| NetInterestIncome | -52.00K | 37.00K | 25.00K | -13.00K |
| InterestExpense | 28.00K | 0.00 | 0.00 | |
| InterestIncome | 34.00K | 41.00K | 36.00K | 8.00K |
| NormalizedIncome | -1.97M | -728.00K | -855.00K | -703.83K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -1.03M | -1.78M | -1.35M | 435.00K |
| TotalExpenses | 2.62M | 765.00K | 880.00K | 1.03M |
| RentExpenseSupplemental | 27.00K | 12.00K | 6.00K | 15.00K |
| TotalOperatingIncomeAsReported | -2.17M | -765.00K | -880.00K | -1.03M |
| DilutedAverageShares | 7.04M | 5.45M | 5.45M | 6.16M |
| BasicAverageShares | 6.73M | 5.45M | 5.45M | 5.32M |
| DilutedEPS | -0.30 | -0.30 | -0.20 | -0.04 |
| BasicEPS | -0.20 | -0.30 | -0.20 | 0.10 |
| DilutedNIAvailtoComStockholders | -1.03M | -1.78M | -1.35M | -225.00K |
| AverageDilutionEarnings | 0.00 | 0.00 | -660.00K | |
| NetIncomeCommonStockholders | -1.03M | -1.78M | -1.35M | 435.00K |
| NetIncome | -1.03M | -1.78M | -1.35M | 435.00K |
| NetIncomeIncludingNoncontrollingInterests | -1.03M | -1.78M | -1.35M | 435.00K |
| NetIncomeContinuousOperations | -1.03M | -1.78M | -1.35M | 435.00K |
| TaxProvision | -130.00K | 0.00 | 0.00 | |
| PretaxIncome | -1.16M | -1.78M | -1.35M | 435.00K |
| OtherIncomeExpense | 1.07M | -1.05M | -493.00K | 1.48M |
| GainOnSaleOfSecurity | 1.07M | -1.05M | -493.00K | 1.48M |
| NetNonOperatingInterestIncomeExpense | -52.00K | 37.00K | 25.00K | -13.00K |
| TotalOtherFinanceCost | 58.00K | 4.00K | 11.00K | 21.00K |
| InterestExpenseNonOperating | 28.00K | 0.00 | 0.00 | |
| InterestIncomeNonOperating | 34.00K | 41.00K | 36.00K | 8.00K |
| OperatingIncome | -2.17M | -765.00K | -880.00K | -1.03M |
| OperatingExpense | 2.17M | 765.00K | 880.00K | 1.03M |
| DepreciationAmortizationDepletionIncomeStatement | 31.00K | 0.00 | 0.00 | |
| DepreciationAndAmortizationInIncomeStatement | 31.00K | 0.00 | 0.00 | |
| Amortization | 31.00K | 0.00 | 0.00 | |
| AmortizationOfIntangiblesIncomeStatement | 31.00K | 0.00 | 0.00 | |
| ResearchAndDevelopment | 98.00K | 31.00K | 30.00K | 30.00K |
| SellingGeneralAndAdministration | 2.05M | 734.00K | 850.00K | 1.00M |
| SellingAndMarketingExpense | 178.00K | 0.00 | 0.00 | |
| GeneralAndAdministrativeExpense | 1.87M | 734.00K | 850.00K | 1.00M |
| OtherGandA | 897.00K | 433.00K | 443.00K | 656.00K |
| InsuranceAndClaims | 100.00K | 119.00K | 202.00K | 229.00K |
| RentAndLandingFees | 27.00K | 12.00K | 6.00K | 15.00K |
| SalariesAndWages | 844.00K | 170.00K | 199.00K | 101.00K |
| GrossProfit | 3.00K | 0.00 | 0.00 | |
| CostOfRevenue | 448.00K | 0.00 | 0.00 | |
| TotalRevenue | 451.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 451.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 881.39M | 544.91M | 544.91M | 544.91M |
| ShareIssued | 881.39M | 544.91M | 544.91M | 544.91M |
| TotalDebt | 138.00K | |||
| TangibleBookValue | -1.57M | 1.84M | 3.62M | 4.95M |
| InvestedCapital | 5.57M | 2.22M | 4.00M | 5.33M |
| WorkingCapital | -867.00K | 1.84M | 3.62M | 6.01M |
| NetTangibleAssets | -1.57M | 1.84M | 3.62M | 4.95M |
| CommonStockEquity | 5.43M | 2.22M | 4.00M | 5.33M |
| TotalCapitalization | 5.43M | 2.22M | 4.00M | 5.33M |
| TotalEquityGrossMinorityInterest | 5.43M | 2.22M | 4.00M | 5.33M |
| StockholdersEquity | 5.43M | 2.22M | 4.00M | 5.33M |
| GainsLossesNotAffectingRetainedEarnings | 20.00K | 20.00K | 20.00K | 20.00K |
| OtherEquityAdjustments | 20.00K | 20.00K | 20.00K | 20.00K |
| RetainedEarnings | -159.01M | -158.25M | -156.47M | -155.13M |
| AdditionalPaidInCapital | 141.29M | 146.33M | 146.33M | 146.33M |
| CapitalStock | 23.14M | 14.12M | 14.12M | 14.12M |
| CommonStock | 23.14M | 14.12M | 14.12M | 14.12M |
| TotalLiabilitiesNetMinorityInterest | 3.12M | 206.00K | 187.00K | 1.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 908.00K | 0.00 | 0.00 | 1.05M |
| DerivativeProductLiabilities | 689.00K | 0.00 | 0.00 | 1.05M |
| NonCurrentDeferredLiabilities | 219.00K | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 219.00K | 0.00 | ||
| CurrentLiabilities | 2.21M | 206.00K | 187.00K | 231.00K |
| OtherCurrentLiabilities | 1.28M | |||
| CurrentDeferredLiabilities | 18.00K | 0.00 | ||
| CurrentDeferredRevenue | 18.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 138.00K | |||
| CurrentDebt | 138.00K | |||
| LineOfCredit | 138.00K | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 53.00K | 0.00 | ||
| PayablesAndAccruedExpenses | 719.00K | 206.00K | 187.00K | 231.00K |
| CurrentAccruedExpenses | 492.00K | 205.00K | 185.00K | 229.00K |
| Payables | 227.00K | 1.00K | 2.00K | 2.00K |
| OtherPayable | 31.00K | |||
| AccountsPayable | 196.00K | 1.00K | 2.00K | 2.00K |
| TotalAssets | 8.55M | 2.43M | 4.19M | 6.62M |
| TotalNonCurrentAssets | 7.21M | 380.00K | 380.00K | 381.00K |
| InvestmentsAndAdvances | 14.00K | 0.00 | ||
| InvestmentinFinancialAssets | 14.00K | 0.00 | ||
| AvailableForSaleSecurities | 14.00K | |||
| GoodwillAndOtherIntangibleAssets | 7.01M | 380.00K | 380.00K | 380.00K |
| OtherIntangibleAssets | 3.82M | 380.00K | 380.00K | 380.00K |
| Goodwill | 3.19M | 0.00 | ||
| NetPPE | 187.00K | 0.00 | 0.00 | 1.00K |
| CurrentAssets | 1.34M | 2.05M | 3.81M | 6.24M |
| OtherCurrentAssets | 47.00K | 11.00K | 14.00K | 16.00K |
| PrepaidAssets | 51.00K | 29.00K | 71.00K | 94.00K |
| Receivables | 150.00K | 29.00K | 71.00K | 94.00K |
| OtherReceivables | 51.00K | 29.00K | 71.00K | 94.00K |
| AccountsReceivable | 99.00K | 0.00 | ||
| AllowanceForDoubtfulAccountsReceivable | -36.00K | 0.00 | ||
| GrossAccountsReceivable | 135.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 1.14M | 2.01M | 3.72M | 6.13M |
| OtherShortTermInvestments | 772.00K | 605.00K | 1.63M | 3.16M |
| CashAndCashEquivalents | 371.00K | 1.40M | 2.09M | 2.97M |
| CashEquivalents | 0.00 | 1.27M | 681.00K | 2.37M |
| CashFinancial | 371.00K | 133.00K | 1.41M | 599.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.67M | -707.00K | -901.00K | -1.05M |
| RepaymentOfDebt | -13.00K | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 1.46M | 0.00 | 0.00 | |
| CapitalExpenditure | -54.00K | |||
| EndCashPosition | 371.00K | 1.40M | 2.09M | 2.97M |
| BeginningCashPosition | 1.40M | 2.09M | 2.97M | 3.63M |
| EffectOfExchangeRateChanges | -15.00K | -27.00K | -10.00K | -6.00K |
| ChangesInCash | -1.01M | -666.00K | -865.00K | -656.00K |
| FinancingCashFlow | 1.45M | 0.00 | 0.00 | 385.00K |
| CashFlowFromContinuingFinancingActivities | 1.45M | 0.00 | 0.00 | 385.00K |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 385.00K | |
| NetCommonStockIssuance | 1.46M | 0.00 | 0.00 | |
| CommonStockIssuance | 1.46M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | -13.00K | 0.00 | 0.00 | |
| NetShortTermDebtIssuance | -13.00K | 0.00 | 0.00 | |
| ShortTermDebtPayments | -13.00K | 0.00 | 0.00 | |
| InvestingCashFlow | -844.00K | 41.00K | 36.00K | 8.00K |
| CashFlowFromContinuingInvestingActivities | -844.00K | 41.00K | 36.00K | 8.00K |
| NetOtherInvestingChanges | -400.00K | |||
| InterestReceivedCFI | 34.00K | 41.00K | 36.00K | 8.00K |
| NetInvestmentPurchaseAndSale | -14.00K | 0.00 | 0.00 | 0.00 |
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | -14.00K | 0.00 | 0.00 | |
| NetBusinessPurchaseAndSale | -410.00K | 0.00 | 0.00 | |
| PurchaseOfBusiness | -410.00K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -54.00K | 0.00 | 0.00 | 0.00 |
| PurchaseOfPPE | -54.00K | 0.00 | 0.00 | 0.00 |
| OperatingCashFlow | -1.62M | -707.00K | -901.00K | -1.05M |
| CashFlowFromContinuingOperatingActivities | -1.62M | -707.00K | -901.00K | -1.05M |
| ChangeInWorkingCapital | 189.00K | 64.00K | -19.00K | -54.00K |
| ChangeInPayablesAndAccruedExpense | 208.00K | 19.00K | -44.00K | -23.00K |
| ChangeInPayable | 208.00K | 19.00K | -44.00K | -23.00K |
| ChangeInAccountPayable | 208.00K | 19.00K | -44.00K | -23.00K |
| ChangeInPrepaidAssets | -58.00K | 45.00K | 25.00K | -31.00K |
| ChangeInReceivables | 39.00K | 0.00 | 0.00 | |
| ChangesInAccountReceivables | 39.00K | 0.00 | 0.00 | |
| OtherNonCashItems | -20.00K | -14.00K | -26.00K | -8.00K |
| StockBasedCompensation | 264.00K | 3.00K | 14.00K | 37.00K |
| UnrealizedGainLossOnInvestmentSecurities | -167.00K | 1.02M | 1.53M | -747.00K |
| DeferredTax | -130.00K | 0.00 | 0.00 | |
| DeferredIncomeTax | -130.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 199.00K | 0.00 | 1.00K | 1.00K |
| DepreciationAndAmortization | 199.00K | 0.00 | 1.00K | 1.00K |
| Depreciation | 0.00 | 1.00K | 1.00K | |
| OperatingGainsLosses | -926.00K | 27.00K | -1.05M | -713.00K |
| GainLossOnInvestmentSecurities | -926.00K | -1.05M | -719.00K | |
| NetForeignCurrencyExchangeGainLoss | 27.00K | 10.00K | 6.00K | |
| NetIncomeFromContinuingOperations | -1.03M | -1.78M | -1.35M | 435.00K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XTLB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|